Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Craig Gerard
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
ChemoCentryx, CCXI
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Gerard is a scientific advisor to the public company ChemoCentryx, which develops small molecule drug inhibitors of complement and chemokine. In his advisory role, Dr. Gerard advises on Complement C5a and C3a receptors, as well as chemokine receptors CCR2 and CCR9. He receives compensation and equity in exchange for his services. Dr. Gerard’s research in the subject grant will be using materials made by the company as a tool compound to explore the role of human C5a Receptor in transgenic mice infected with Leukocidin containing MRSA bacterial. Although Dr. Gerard’s research is distinct from the Company’s work, the results do have the potential to indirectly benefit the Company, which is conducting a clinical trial to see if the C5a receptor antagonists treats inflammation of blood vessels called vasculitis.
Targeting Innate Immunity in Staphylococcal Infection
Project Narrative Over the past several years, infections with methicillin-resistant Staphylococcus aureus strains (MRSA) have become increasingly prevalent in the US and worldwide. Among a number of mechanisms this bacteria has evolved to evade host defense are the toxins, Panton-Valentine leukocidin (PVL) and ?-hemolysin (?HL). These toxins selectively lyse certain classes of white blood cells, including polymorphonuclear neutrophils and macrophages in a highly species-specific manner, with human among the most sensitive. Recently, it has been demonstrated that the receptors for human anaphylatoxin, C5a, C5aR and C5L2, act as binding sites for both PVL and ?HL. Based on this finding, we hypothesize that small molecule antagonists of the C5a receptor will be useful in treating Staphylococcal infections as an adjunct to antibiotic therapy.
Filed on December 30, 2015.
Tell us what you know about Craig Gerard's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Craig Gerard filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Craig Gerard | Boston Children's Hospital | Conflict of Interest | ChemoCentryx, CCXI | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.